Genome-wide association study of antidepressant response: Involvement of the inorganic cation transmembrane transporter activity pathway

BMC Psychiatry

Volumn 16, Issue 1, 2016, Pages

  Cocchi, Enrico ^a   Fabbri, Chiara ^a   Han, Changsu ^b   Lee, Soo Jung ^c   Patkar, Ashwin A ^d   Masand, Prakash S ^e   Pae, Chi Un ^c,d   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Korea University College of Medicine   (South Korea)

^c The Catholic University of Korea College of Medicine   (South Korea)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Global Medical Education Inc   (United States)

Author keywords

Antidepressant; Calcium channel; Cation transmembrane transporter; Gene; GWAS; Major depression; Pathway; Pharmacogenomics

Indexed keywords

ANTIDEPRESSANT AGENT; CATION TRANSPORT PROTEIN; ORGANIC CATION TRANSPORTER;

ADULT; AGED; ARTICLE; CACNA1A GENE; CACNA1C GENE; CACNB2 GENE; CONTROLLED STUDY; CTNNA3 GENE; DISEASE SEVERITY; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE REPLICATION; GENETIC ASSOCIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPING TECHNIQUE; HAMILTON DEPRESSION RATING SCALE; HUMAN; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MAJOR DEPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ASIAN CONTINENTAL ANCESTRY GROUP; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETICS; GENOTYPE; MALE; METABOLISM; PHENOTYPE;

ADULT; ANTIDEPRESSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; ORGANIC CATION TRANSPORT PROTEINS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84990848586     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-016-0813-x     Document Type: Article

References (61)

1. Tansey KE, Guipponi M, Hu X, Domenici E, Lewis G, Malafosse A, Wendland JR, Lewis CM, McGuffin P, Uher R. Contribution of common genetic variants to antidepressant response. Biol Psychiatry. 2013;73:679-82.
2. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, Reinalda MS, Slager SL, McGrath PJ, Hamilton SP. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry. 2010;67:133-8.
3. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010;167:555-64.
4. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, Kohli MA, Hennings JM, Horstmann S, Kloiber S, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009;66:966-75.
5. Hunter AM, Leuchter AF, Power RA, Muthen B, McGrath PJ, Lewis CM, Cook IA, Garriock HA, McGuffin P, Uher R, et al. A genome-wide association study of a sustained pattern of antidepressant response. J Psychiatr Res. 2013;47:1157-65.
6. Tansey KE, Guipponi M, Perroud N, Bondolfi G, Domenici E, Evans D, Hall SK, Hauser J, Henigsberg N, Hu X, et al. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a metaanalysis. PLoS Med. 2012;9:e1001326.
7. GENDEP, MARS, STAR*D, Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry. 2013;170:207-17.
8. Sasayama D, Hiraishi A, Tatsumi M, Kamijima K, Ikeda M, Umene-Nakano W, Yoshimura R, Nakamura J, Iwata N, Kunugi H. Possible association of CUX1 gene polymorphisms with antidepressant response in major depressive disorder. Pharmacogen J. 2013;13:354-8.
9. Myung W, Kim J, Lim SW, Shim S, Won HH, Kim S, Lee MS, Chang HS, Kim JW, Carroll BJ, et al. A genome-wide association study of antidepressant response in Koreans. Translat Psychiatry. 2015;5:e633.
10. Biernacka JM, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmoller J, Chen CH, et al. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Translat Psychiatry. 2015;5:e553.
11. Jin L, Zuo XY, Su WY, Zhao XL, Yuan MQ, Han LZ, Zhao X, Chen YD, Rao SQ. Pathway-based Analysis Tools for Complex Diseases: A Review. Genomics Proteomics Bioinformatics. 2014;12:210-20.
12. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38:W214-20.
13. Segre AV, Consortium D, investigators M, Groop L, Mootha VK, Daly MJ, Altshuler D. Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. PLoS Genet. 2010;6(8). doi:10.1371/journal.pgen.1001058.
14. Lee PH, O'Dushlaine C, Thomas B, Purcell SM. INRICH: interval-based enrichment analysis for genome-wide association studies. Bioinformatics. 2012;28:1797-9.
15. Holmans P, Green EK, Pahwa JS, Ferreira MA, Purcell SM, Sklar P, Wellcome Trust Case-Control C, Owen MJ, O'Donovan MC, Craddock N. Gene ontology analysis of GWA study data sets provides insights into the biology of bipolar disorder. Am J Hum Genet. 2009;85:13-24.
16. Nam D, Kim J, Kim SY, Kim S. GSA-SNP: a general approach for gene set analysis of polymorphisms. Nucleic Acids Res. 2010;38:W749-54.
17. Fabbri C, Serretti A. Genetics of long-term treatment outcome in bipolar disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2015;65:17-24.
18. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). New York: Biometrics Research: New York State Psychiatric Institute; 2002.
19. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
20. Howland RH. Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 1: study design. J Psychosoc Nurs Ment Health Serv. 2008;46:21-4.
21. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, Crismon ML, Shores-Wilson K, Toprac MG, Dennehy EB, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDSSR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34:73-82.
22. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
23. Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT. Data quality control in genetic case-control association studies. Nat Protoc. 2010; 5:1564-73.
24. Shyn SI, Shi J, Kraft JB, Potash JB, Knowles JA, Weissman MM, Garriock HA, Yokoyama JS, McGrath PJ, Peters EJ, et al. Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. Mol Psychiatry. 2011;16:202-15.
25. Purcell S, Neale B, Todd-Brown K, Thomas L, FerreiraMA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559-75.
26. Fabbri C, Di Girolamo G, Serretti A. Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet. 2013;162B:487-520.
27. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, Christmas R, Avila-Campilo I, Creech M, Gross B, et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc. 2007;2:2366-82.
28. Montojo J, Zuberi K, Rodriguez H, Kazi F, Wright G, Donaldson SL, Morris Q, Bader GD. GeneMANIA Cytoscape plugin: fast gene function predictions on the desktop. Bioinformatics. 2010;26:2927-8.
29. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25-9.
30. Drago A, Cocchi E, Crisafulli C, Serretti A. A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment. J Neural Transm (Vienna). 2015;122(3):465-75.
31. Abatangelo L, Maglietta R, Distaso A, D'Addabbo A, Creanza TM, Mukherjee S, Ancona N. Comparative study of gene set enrichment methods. BMC Bioinformatics. 2009;10:275.
32. Fridley BL, Jenkins GD, Biernacka JM. Self-contained gene-set analysis of expression data: an evaluation of existing and novel methods. PLoS One. 2010;5:e12693.
33. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics. 2003;19:149-50.
34. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175-91.
35. Lauks J, Klemmer P, Farzana F, Karupothula R, Zalm R, Cooke NE, Li KW, Smit AB, Toonen R, Verhage M. Synapse associated protein 102 (SAP102) binds the C-terminal part of the scaffolding protein neurobeachin. PLoS One. 2012;7:e39420.
36. Nair R, Lauks J, Jung S, Cooke NE, de Wit H, Brose N, Kilimann MW, Verhage M, Rhee J. Neurobeachin regulates neurotransmitter receptor trafficking to synapses. J Cell Biol. 2013;200:61-80.
37. Drago A, Crisafulli C, Sidoti A, Serretti A. The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes. Prog Neurobiol. 2011;94:418-60.
38. Rogowski K, van Dijk J, Magiera MM, Bosc C, Deloulme JC, Bosson A, Peris L, Gold ND, Lacroix B, Bosch Grau M, et al. A family of protein-deglutamylating enzymes associated with neurodegeneration. Cell. 2010;143:564-78.
39. Budziszewska B, Jaworska-Feil L, Tetich M, Basta-Kaim A, Kubera M, Leskiewicz M, Lason W. Regulation of the human corticotropinreleasing-hormone gene promoter activity by antidepressant drugs in Neuro-2A and AtT-20 cells. Neuropsychopharmacology. 2004;29:785-94.
40. Kirchheiner J, Nickchen K, Sasse J, Bauer M, Roots I, Brockmoller J. A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogen J. 2007;7:48-55.
41. Tiwari AK, Zai CC, Sajeev G, Arenovich T, Muller DJ, Kennedy JL. Analysis of 34 candidate genes in bupropion and placebo remission. Int J Neuropsychopharmacol. 2013;16:771-81.
42. Cross-Disorder, Group, of, the, Psychiatric, Genomics, Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013;381:1371-9.
43. Wang N, Zhang GF, Liu XY, Sun HL, Wang XM, Qiu LL, Yang C, Yang JJ. Downregulation of neuregulin 1-ErbB4 signaling in parvalbumin interneurons in the rat brain may contribute to the antidepressant properties of ketamine. J Mol Neurosci. 2014;54:211-8.
44. Borglum AD, Demontis D, Grove J, Pallesen J, Hollegaard MV, Pedersen CB, Hedemand A, Mattheisen M, Uitterlinden A, Nyegaard M, et al. Genome-wide study of association and interaction with maternal cytomegalovirus infection suggests new schizophrenia loci. Mol Psychiatry. 2014;19:325-33.
45. Mostany R, Valdizan EM, Pazos A. A role for nuclear beta-catenin in SNRI antidepressant-induced hippocampal cell proliferation. Neuropharmacology. 2008;55:18-26.
46. Fabbri C, Marsano A, Albani D, Chierchia A, Calati R, Drago A, Crisafulli C, Calabro M, Kasper S, Lanzenberger R, et al. PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. Pharmacogen J. 2014;14:463-72.
47. Lin JY, Jiang MY, Kan ZM, Chu Y. Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis. J Affect Disord. 2014;168:430-8.
48. Hu Y, Xing J, Wang L, Huang M, Guo X, Chen L, Lin M, Zhou Y, Liu Z, Zhou Z, et al. RGS22, a novel cancer/testis antigen, inhibits epithelial cell invasion and metastasis. Clin Exp Metastasis. 2011;28:541-9.
49. Habuchi H, Tanaka M, Habuchi O, Yoshida K, Suzuki H, Ban K, Kimata K. The occurrence of three isoforms of heparan sulfate 6-O-sulfotransferase having different specificities for hexuronic acid adjacent to the targeted Nsulfoglucosamine. J Biol Chem. 2000;275:2859-68.
50. Giovannetti E, Wang Q, Avan A, Funel N, Lagerweij T, Lee JH, Caretti V, van der Velde A, Boggi U, Wang Y, et al. Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. J Natl Cancer Inst. 2014;106:djt346.
51. Elakovic I, Djordjevic A, Adzic M, Djordjevic J, Radojcic M, Matic G. Gender-specific response of brain corticosteroid receptors to stress and fluoxetine. Brain Res. 2011;1384:61-8.
52. Heydendael W, Jacobson L. Differential effects of imipramine and phenelzine on corticosteroid receptor gene expression in mouse brain: potential relevance to antidepressant response. Brain Res. 2008;1238:93-107.
53. Malki K, Campbell J, Davies M, Keers R, Uher R, Ward M, Paya-Cano J, Aitchinson KJ, Binder E, Sluyter F, et al. Pharmacoproteomic investigation into antidepressant response in two mouse inbred strains. Proteomics. 2012;12:2355-65.
54. Dao DT, Mahon PB, Cai X, Kovacsics CE, Blackwell RA, Arad M, Shi J, Zandi PP, O'Donnell P, Bipolar Genome Study C, et al. Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans. Biol Psychiatry. 2010;68:801-10.
55. Bhat S, Dao DT, Terrillion CE, Arad M, Smith RJ, Soldatov NM, Gould TD. CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. Prog Neurobiol. 2012;99:1-14.
56. Koncz I, Szasz BK, Szabo SI, Kiss JP, Mike A, Lendvai B, Sylvester Vizi E, Zelles T. The tricyclic antidepressant desipramine inhibited the neurotoxic, kainateinduced [Ca(2+)]i increases in CA1 pyramidal cells in acute hippocampal slices. Brain Res Bull. 2014;104:42-51.
57. Zhang W, Meehan J, Su Z, Ng HW, Shu M, Luo H, Ge W, Perkins R, Tong W, Hong H. Whole genome sequencing of 35 individuals provides insights into the genetic architecture of Korean population. BMC Bioinformatics. 2014;15 Suppl 11:S6.
58. Lin P, Hartz SM, Zhang Z, Saccone SF, Wang J, Tischfield JA, Edenberg HJ, Kramer JR, A MG, Bierut LJ, et al. A new statistic to evaluate imputation reliability. PLoS One. 2010;5:e9697.
59. Ortega VE, Meyers DA. Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. J Allergy Clin Immunol. 2014;133:16-26.
60. Jiang L, Yin J, Ye L, Yang J, Hemani G, Liu AJ, Zou H, He D, Sun L, Zeng X, et al. Novel risk loci for rheumatoid arthritis in Han Chinese and congruence with risk variants in Europeans. Arthritis Rheumatol. 2014;66:1121-32.
61. Niitsu T, Fabbri C, Bentini F, Serretti A. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;45:183-94.